These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 29508763)

  • 1. Novel therapies for malignant pleural mesothelioma.
    Scherpereel A; Wallyn F; Albelda SM; Munck C
    Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
    Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
    Kondola S; Manners D; Nowak AK
    Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Searching for targets for the systemic therapy of mesothelioma.
    Stahel RA; Weder W; Felley-Bosco E; Petrausch U; Curioni-Fontecedro A; Schmitt-Opitz I; Peters S
    Ann Oncol; 2015 Aug; 26(8):1649-60. PubMed ID: 25722383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
    Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
    Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
    Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
    Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
    Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
    Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
    Christoph DC; Eberhardt WE
    Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies currently in Phase II trials for malignant pleural mesothelioma.
    Pinton G; Manente AG; Tavian D; Moro L; Mutti L
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1255-63. PubMed ID: 23815672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.